Oruka's Psoriasis Data Rattles AbbVie's Skyrizi Franchise

What happened

Oruka Therapeutics released Phase 2 data showing 66% of psoriasis patients achieved completely clear skin after 16 weeks, directly challenging AbbVie's Skyrizi in its core indication. Skyrizi is AbbVie's largest drug with a 2026 revenue guide of $21.5B, and psoriasis represents a key growth driver. While Skyrizi currently holds a U.S. biologic TRx share above 45%, this early-stage competitor from a novel mechanism could pressure future growth expectations. AbbVie's investment thesis hinges on continued volume-led expansion of Skyrizi and Rinvoq, and any credible competitive threat warrants close monitoring. The existing WAIT rating already priced in execution risks, but this news introduces a new competitive vector that may accelerate the need for pipeline diversification.

Implication

AbbVie's immunology franchise, particularly Skyrizi, faces a new competitive threat from Oruka's high-efficacy psoriasis treatment. While AbbVie's current guidance and share metrics are strong, the market may begin discounting future growth if this competitor advances. The Rinvoq 2037 exclusivity and aesthetics stabilization are separate pillars, but Skyrizi is the primary earnings driver. Investors should look for AbbVie's pipeline response or M&A to counter, but near-term, the risk-reward remains unattractive at current multiples. We maintain our WAIT stance until we see whether Skyrizi can defend share or AbbVie articulates a credible long-term plan.

Thesis delta

This news introduces a credible late-stage competitor to Skyrizi in psoriasis, shifting the competitive landscape from a steady share-capture narrative to one with potential erosion risk. While early, it raises the probability of the bear case where Skyrizi growth decelerates due to competition, not just payer actions. The thesis now requires tracking Oruka's Phase 3 data as a new variable, increasing uncertainty.